Document Detail

Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment.
MedLine Citation:
PMID:  22008284     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To describe predictors of visual outcome in patients treated with intravitreal ranibizumab for choroidal neovascularisation (CNV) in age-related macular degeneration (AMD).
METHODS: Retrospective review of 279 patients with CNV in AMD who fulfilled MARINA/ANCHOR study eligibility criteria and were treated with repeated intravitreal injections of ranibizumab 0.5 mg in routine clinical practice, beginning with three initial injections at 4-week intervals followed by individualized retreatment for the subsequent 9 months. Study parameters included best-corrected visual acuity (BCVA) and morphological characteristics.
RESULTS:   Mean BCVA relative to baseline was +4.7 (p < 0.0001), +4.2 (p < 0.0001)and -0.4 (p > 0.667) Early Treatment Diabetic Retinopathy Study letters after 3, 6 and 12 months, respectively, after a mean of 5.1 injections when the proportion of patients with BCVA ≥ 70 letters had doubled compared with baseline. Predictive factors for BCVA ≤ 35 letters after 12 months were BCVA ≤ 35 letters at baseline and month 3 (p < 0.0001) while BCVA ≥ 70 letters at month 12 was associated with BCVA ≥ 70 letters at baseline and month 3 (p < 0.001) and with total lesion size <4 DA (p = 0.0147).
CONCLUSION:   Under a ranibizumab regimen with substantially fewer injections than with fixed four-weekly injection regimens, BCVA was improved compared with the natural history of neovascular AMD, but did not achieve the visual gain observed in randomized clinical trials using fixed 4-week retreatment. Visual acuity at month 3, after the initial fixed-interval injections, was the strongest predictor of BCVA at month 12.
Sara B Bloch; Morten la Cour; Birgit Sander; Louise K H Hansen; Josefine Fuchs; Henrik Lund-Andersen; Michael Larsen
Related Documents :
25168824 - Unilateral choroidal granulomas complicated by choroidal neovascular membrane treated s...
8678624 - Cd14 expression in injured patients correlates with outcome.
15513354 - Reduced relapse rate in duodenal ulcer disease leads to normalization of psychological ...
22036124 - Chronic oral anticoagulant therapy in carotid artery stenting: the un-necessity of peri...
16699254 - Long-term bosentan in chronic thromboembolic pulmonary hypertension.
22644174 - Efficacy of frovatriptan versus other triptans in the acute treatment of menstrual migr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-10-19
Journal Detail:
Title:  Acta ophthalmologica     Volume:  91     ISSN:  1755-3768     ISO Abbreviation:  Acta Ophthalmol     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-25     Completed Date:  2013-04-26     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  101468102     Medline TA:  Acta Ophthalmol     Country:  England    
Other Details:
Languages:  eng     Pagination:  42-7     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. Acta Ophthalmologica © 2011 Acta Ophthalmologica Scandinavica Foundation.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Angiogenesis Inhibitors / administration & dosage*,  therapeutic use
Antibodies, Monoclonal, Humanized / administration & dosage*,  therapeutic use
Intravitreal Injections
Middle Aged
Retrospective Studies
Time Factors
Treatment Outcome
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Visual Acuity / physiology*
Wet Macular Degeneration / drug therapy*,  physiopathology
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal, Humanized; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/ranibizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Next Document:  Cloning and functional analysis of PKZ (PKR-like) from grass carp (Ctenopharyngodon idellus).